World’s First AI Vaccine Targets Future Pandemics
Researchers have initiated human trials for an AI-designed vaccine aimed at safeguarding against emerging virus threats.
Researchers have utilized artificial intelligence to create a “fundamentally new” type of vaccine, which they claim could offer protection against a wide array of viruses and aid in preventing future pandemics.
Researchers at the University of Cambridge report that this study marks the first instance of a vaccine’s essential component being entirely developed by artificial intelligence and subsequently tested in human subjects.
The vaccine was developed to be effective against all coronaviruses, including Covid variants and viruses present in animals that could potentially lead to future outbreaks in humans.
While the research is still in its initial phases, the team is actively developing distinct vaccines aimed at influenza and Ebola.
Vaccines prepare the immune system to identify and combat infections. However, numerous viruses continuously evolve through mutation, resulting in diminished effectiveness of existing vaccines over time. This scenario explains the necessity for regular updates to Covid and seasonal flu vaccines.
“We’re always behind,” stated Prof. Jonathan Heeney of the University of Cambridge, adding, “What we’re trying to do is get ahead of the curve,” aiming to be so far ahead that they could safeguard against new outbreaks or pandemics.
Traditional vaccines are generally developed based on current virus strains. The researchers at Cambridge utilized genetic data gathered from various coronaviruses identified through surveillance programs aimed at monitoring potential viral threats.
The genetic information was analyzed by AI, which created a “super-antigen” to help the immune system recognize and fight against a whole group of viruses, including mutated strains and new infections that could jump from animals to humans.
Antigens serve as essential elements of vaccines, as they instruct the immune system on what to target.
Heeney stated that the trial marked the first instance of an AI-designed antigen being tested on humans. He called the technology “surprising” and said it’s “amazing what we can do with it for humanity.”
Heeney informed BBC News: “This initiative focuses on developing vaccines that safeguard us, not only against the viruses we face today but also against potential future outbreaks or diseases.”
“This effort represents a crucial change in our approach to pandemic preparedness.”
The initial trial included 39 participants and aimed to evaluate safety. A second study involving approximately 200 participants is anticipated to offer a more detailed understanding of how effectively the vaccine activates the immune system.
Findings published in the Journal of Infection indicate that the vaccine’s effect on the immune system was “modest,” yet researchers remain optimistic about the results.
Prof Saul Faust, who conducted some of the trials at the University of Southampton, expressed that the AI-designed vaccine “definitely has potential” and is “really exciting.”
He stated to the BBC, “What’s truly fascinating is that the technology has significantly improved in designing vaccines for potential pandemics as viruses evolve.”
The Cambridge team is conducting animal studies on a universal seasonal flu vaccine that would not require annual updates, along with an H5N1 bird flu vaccine in preparation for a potential human pandemic caused by the virus.
Researchers are investigating vaccines for viral hemorrhagic fevers, such as Ebola. The ongoing outbreak in the Democratic Republic of the Congo is attributed to a species for which a vaccine has not yet been created.
